Restore Robotics Secures FDA 510(k) Clearance for Two New da Vinci Xi® Instruments; Medtronic Wins FDA Approval for OmniaSecure™ Defibrillation Lead Enabling Conduction System Pacing; Bebird Introduces EarSight Ultra; BD Introduces AI-Driven Medication Dispensing System in Europe; i-Lumen Scientific Secures FDA IDE Approval to Launch U.S. Enrollment for i-SIGHT2 Dry AMD Trial; Belay Diagnostics Highlights 82% Clinical Impact Rate in CNS Lymphoma Evaluation

Restore Robotics Received FDA 510(k) Clearance for Two Additional da Vinci Xi® Robotic Instruments 

On 31 March 2026, Restore Robotics announced that it had received an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the remanufacturing of two more da Vinci Xi robotic surgical instruments. This achievement expanded the company’s portfolio of cleared instruments and reinforced its position in the robotic instrument remanufacturing space.

With these new clearances, the company continued to advance its mission of providing hospitals and surgical centers with cost-effective, high-quality, and sustainable alternatives to purchasing new instruments from original equipment manufacturers. According to CEO Clif Parker, the clearances represented a significant step toward improving the economics of robotic surgery. By broadening its remanufacturing capabilities across frequently used instruments, the company enabled healthcare providers to lower costs while maintaining the performance and reliability required for surgical procedures.

Through its partnership with Encore Medical Device Repair, Restore Robotics scaled the nationwide distribution of its remanufactured instruments. The expanded product portfolio allowed hospitals to achieve greater cost savings across a wider range of robotic instrument expenditures. Hospitals participating in the program benefited from reduced costs compared to OEM instruments, improved sustainability through instrument reuse, and seamless integration into existing robotic surgery workflows.

“These additional FDA clearances mark another major step forward in our effort to transform the economics of robotic surgery,” said Clif Parker, CEO of Restore Robotics. “By expanding our remanufacturing capabilities across more high-utilization instruments, we are enabling healthcare providers to significantly reduce costs while maintaining the performance and reliability surgeons expect.”

As per DelveInsight’s “Surgical Robotic System Market Report,” the global surgical robotic system market size is expected to increase from USD 11,082.32 million in 2025 to USD 29,785.13 million by 2034, growing at a CAGR of 13.21% during the forecast period from 2026 to 2034. The rising incidence of chronic disorders such as cancer, cardiovascular diseases, and orthopedic conditions is significantly boosting the demand for advanced surgical interventions, thereby propelling the growth of the Surgical Robotic Systems Market. As chronic conditions often require complex, high-precision surgeries, robotic-assisted procedures offer enhanced accuracy, minimal invasiveness, and quicker recovery times, making them highly suitable for treating such ailments. Simultaneously, the increasing number of surgical procedures globally, driven by a growing aging population and a higher prevalence of lifestyle-related health issues, is further escalating the need for efficient and precise surgical tools. In response, key Surgical Robotic System Companies are heavily investing in product development activities, focusing on innovations such as compact robotic platforms, AI integration, and enhanced visualization systems. These advancements not only expand the scope of robotic surgery across specialties but also improve surgical outcomes, thereby contributing to the growth of the surgical robotic systems market forecast period from 2026 to 2034.

Medtronic OmniaSecure™ Defibrillation Lead, the First Lead of its Kind, Received FDA Approval for Conduction System Pacing 

On 24 March 2026, Medtronic plc announced that it had received approval from the U.S. Food and Drug Administration for an expanded indication of its OmniaSecure™ defibrillation lead. The approval allowed the device to be used in the left bundle branch (LBB) area, enabling conduction system pacing (CSP), a method that more closely replicates the heart’s natural electrical activity.

This milestone made OmniaSecure the first defibrillation lead approved for placement in the LBB region. Designed to connect with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), the lead was developed to manage life-threatening arrhythmias such as ventricular tachycardia, ventricular fibrillation, and bradyarrhythmias. Its compact design (4.7 French) made it the smallest defibrillation lead available, and it was approved for both adults and pediatric patients aged 12 years and older.

Built on the foundation of the SelectSecure Model 3830 pacing lead, the OmniaSecure lead featured a lumenless structure that enhanced durability and enabled catheter-based delivery for precise placement. By leveraging CSP, the device could activate the heart’s intrinsic conduction pathways, potentially reducing complications associated with conventional pacing approaches.

The approval was supported by findings from the LEADR LBBAP trial, which demonstrated strong safety and efficacy outcomes, including a 100% defibrillation success rate at implantation and a low complication rate at three months. The therapy could also be combined with left ventricular pacing in advanced approaches such as LOT-CRT to further improve synchronization and patient outcomes.

“Conduction system pacing is a rapidly growing therapy for patients who need a pacemaker. Now, patients who require a defibrillator and pacing have an option that can safely deliver life-saving defibrillation therapy and activate the heart’s natural electrical system to enable a more synchronous, physiologic pattern,” said Trevor Cook, vice president and general manager of the Defibrillation Solutions business, which is part of the Cardiac Rhythm Management operating unit at Medtronic. “This approval underscores the versatility of the OmniaSecure defibrillation lead and supports its use across a variety of implant approaches to best serve a broad range of patients.” 

As per DelveInsight’s “Defibrillators Market Report,” the defibrillators market was valued at USD 10.19 billion in 2023, growing at a CAGR of 3.11% during the forecast period from 2025 to 2032, to reach USD 12.24 billion by 2032. The defibrillator market is observing substantial market growth, primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases, including atrial fibrillation and coronary artery disease (CAD), innovative product development activities by leading companies, and the rising geriatric population, which are expected to escalate the overall growth of the defibrillators market during the forecast period from 2025 to 2032.

Bebird Launches EarSight Ultra: The 5G-Powered Ear Care Solution for Modern Families Pursuing a Quality Life 

On 01 April 2026, Bebird, a global innovator in smart personal care, introduced the EarSight Ultra, a landmark device designed for parents focused on proactive health and improved family well-being. The product brought professional ear care into the home and was built on three core pillars: 5G-powered connectivity, high visual clarity, and comprehensive family safety. The device featured an integrated 5G chip that enabled smooth, real-time video streaming without lag. This allowed parents to monitor the ear cleaning process with precision, ensuring a safe and controlled experience for both children and adults.

EarSight Ultra also incorporated a patented 4P endoscope that delivered 2K ultra-clear imaging. This enhanced visual capability helped users perform ear care with greater accuracy and confidence. To ensure safety, the device included an adjustable depth stop collar to prevent over-insertion, maintained a constant skin-friendly temperature of 36°C, and used a multi-axis gyroscope for stable navigation. It also came with five individual 6-in-1 earpick kits to avoid cross-contamination, along with an ear-drop dispenser for targeted treatment.

Designed for modern households, the device empowered families to adopt more informed and preventive health practices. According to a company spokesperson, the product was developed to provide clarity, control, and confidence in family wellness routines, transforming ear care into a precise and visible process suitable for users aged three and above. The EarSight Ultra served as a versatile solution for managing children’s earwax, addressing swimmer’s ear, and maintaining hygiene related to earbud usage among adults, supporting proactive ear health management.

As per DelveInsight’s “ENT Devices Market Report,” the global ENT devices market is expected to increase from USD 23,750.10 million in 2024 to USD 38,588.11 million by 2032, growing at a CAGR of 6.30% during the forecast period from 2025 to 2032. The ENT devices market is experiencing robust growth driven by the rising global prevalence of ear, nose, and throat disorders, which is further exacerbated by the increasing geriatric population and the growing burden of chronic conditions like cancer and allergic rhinitis. Concurrently, a surge in demand for minimally invasive procedures is accelerating market expansion, as patients and clinicians favor these techniques for their shorter recovery times, reduced pain, and improved outcomes. This trend is amplified by a boom in aesthetic and reconstructive plastic surgeries that require specialized ENT devices. Moreover, continuous technological innovation is a key catalyst, with advancements such as AI-powered diagnostics, robotic-assisted surgical systems, and the development of less-invasive instruments making ENT care more precise and effective than ever before.

BD Launched AI-Enabled Medication Dispensing System to the European Market 

On 01 March 2026, Becton, Dickinson and Company (BD), a global medical technology leader, announced the launch of the BD® Pyxis™ Pro Dispensing Solution and the BD® Incada™ Connected Care Platform in Europe. The new medication dispensing system combined advanced automation with AI-driven insights to modernize medication management, reduce workflow disruptions, and improve operational efficiency, enabling clinicians to dedicate more time to patient care.

The BD Pyxis™ Pro Dispensing Solution provided quick and reliable access to medications at the point of care. It featured a flexible and stackable design that increased medication storage capacity within a similar footprint, supporting both refrigerated and ambient storage needs. The system also incorporated enhanced security features, including RFID badge scanning, wireless barcode scanners, and illuminated bins, which streamlined medication retrieval and improved controlled substance management.

Building on its existing deployment in the United States, BD expanded its AI-powered BD Incada™ Analytics platform to European hospitals and health systems. The platform, built on Amazon Web Services’ cloud infrastructure, utilized advanced technologies such as natural language search and scalable data processing to manage information generated by millions of connected BD devices.

With BD Incada™ Analytics, clinicians gained enterprise-wide visibility into medication inventory through customizable dashboards, allowing them to identify usage patterns, ensure medication availability, reduce waste, and improve workforce efficiency. In Europe, BD leveraged the AWS European Sovereign Cloud to address digital sovereignty requirements, ensuring that healthcare systems could maintain data security and compliance while benefiting from high-performance cloud capabilities and innovative solutions.

“BD’s innovations in medication management are setting a new standard for unified, data-driven healthcare operations,” said Esteban Rossi, vice president and general manager for Medication Management Solutions, EMEA at BD. “Delivering the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Platform directly to European hospitals empowers our customers to strengthen medication availability, improve efficiency and enhance patient care.”

According to DelveInsight’s “Digital Health Market Report”, the digital health market was valued at USD 178.37 billion in 2024 and is estimated to grow at a CAGR of 18.25% during the forecast period from 2025 to 2032 to reach USD 486.55 billion by 2032. The increase in AI-powered algorithms, which help in analyzing large datasets to identify patterns and insights that aid in early disease detection and intervention, is boosting the market of digital health. Additionally, the increasing medical conditions necessitating regular check-ups will probably escalate the market of digital health, as regular therapy sessions, psychiatric consultations, and children requiring frequent health check-ups for vaccinations, growth monitoring, and skin conditions often need ongoing evaluation and treatment adjustments, which increases the demand for digital health. Furthermore, the increase in mobile health applications promoting proactive healthcare management, reducing emergency room visits, and lowering healthcare costs associated with chronic disease management further propels the market. Additionally, government initiatives, including the launch of national telehealth programs, subsidizing digital health solutions for underserved populations, and promoting interoperability standards for health information exchange, collectively boost the digital health market during the forecast period from 2025 to 2032.

i-Lumen Scientific Received FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD 

On 31 March 2026, i-Lumen Scientific, Inc., a company specializing in energy-based innovations for ophthalmology, announced that it had received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to begin patient enrollment in the United States for its i-SIGHT2 pivotal study. The study was designed to evaluate the impact of the company’s non-invasive bioelectric stimulation therapy on visual acuity in patients suffering from intermediate to advanced dry age-related macular degeneration (AMD).

The IDE approval marked a significant milestone in the global expansion of the i-SIGHT2 study, which was already actively enrolling and treating participants in the United Kingdom, Australia, and New Zealand. The trial was planned to enroll a total of 120 participants across all sites, with U.S. enrollment expected to commence in late April 2026.

According to the company’s CEO, John VeLure, the approval represented an important step in extending the study into the United States, which has a large population of patients affected by intermediate to advanced dry AMD. The expansion reflected the company’s commitment to developing a non-invasive, office-based therapeutic solution for both physicians and patients.

The study also achieved an operational milestone, as the first participant had been successfully randomized and treated in the United Kingdom at London North West University Healthcare NHS Trust under the leadership of Christiana Dinah, Director of Research and Innovation. She noted that patients with this stage of AMD have very limited treatment options and highlighted the potential of the non-invasive therapy as a promising area of research.

Age-related macular degeneration was described as a leading cause of vision loss among individuals over the age of 50 worldwide, with prevalence expected to increase significantly in the coming years. Patients with intermediate to advanced dry AMD were reported to experience progressive central vision loss, severely affecting daily activities such as reading, driving, and recognizing faces.

The disease was explained as resulting from dysfunction in retinal cells within the macula, including photoreceptors and the retinal pigment epithelium (RPE). The company’s therapy utilized proprietary microcurrent stimulation to improve RPE function and restore retinal electrophysiology, aiming to slow or improve vision loss associated with the condition.

According to DelveInsight’s ”Ophthalmic Devices Market Report,” the global ophthalmic devices market is expected to increase from USD 31,902.50 million in 2024 to USD 44,247.53 million by 2032, growing at a CAGR of 7.13% during the forecast period from 2025 to 2032. The global ophthalmic device market is witnessing robust growth, primarily driven by the rising incidence of eye disorders such as cataracts, glaucoma, age-related macular degeneration, diabetic retinopathy, and refractive errors. Factors such as aging populations, increasing prevalence of diabetes and hypertension, and greater exposure to digital screens are significantly contributing to the growing patient pool. This surge in eye-related conditions is fueling demand for advanced diagnostic, surgical, and vision correction devices, prompting continuous innovation and adoption of technologies like minimally invasive surgeries, laser systems, and AI-enabled diagnostics. Consequently, the escalating burden of eye diseases is a key catalyst shaping the expansion of the ophthalmic device market worldwide.

Belay Diagnostics Reported 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study 

On 24 March 2026, Belay Diagnostics announced that a retrospective study had been published demonstrating the clinical value of its Summit and Vantage tests in patients with central nervous system (CNS) lymphoma. The study evaluated 50 specimens from 48 patients during the first year of the tests’ commercial availability and found that the assays delivered meaningful clinical impact in 82% of cases.

The findings showed that the tests had helped clinicians address key diagnostic challenges, including resolving uncertain differential diagnoses, confirming disease recurrence or progression, supporting disease stratification, and assisting in clinical trial decision-making where traditional diagnostic tools had limited sensitivity. In 64% of the samples, Summit successfully identified clinically relevant genetic variants, while negative results also proved useful in ruling out CNS lymphoma or confirming treatment response.

Notably, in one highlighted case, Summit was the only test that provided actionable insights after other diagnostic methods, such as MRI, biopsy, and blood-based testing, had yielded inconclusive results. The study also identified key genetic alterations, including MYD88, TP53, and CD79B, which are strongly associated with CNS lymphoma. Additionally, findings related to aneuploidy helped indicate potential metastatic disease in certain cases, while longitudinal monitoring demonstrated treatment effectiveness through the absence of previously detected variants.

According to DelveInsight’s “Molecular Diagnostics Market Report,”  the molecular diagnostics market was valued at USD 9.56 billion in 2024, growing at a CAGR of 9.21% during the forecast period from 2025 to 2032, to reach USD 16.12 billion by 2032. The molecular diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases, including HIV, Hepatitis B and Hepatitis C, Influenza, and human papillomavirus (HPV). The introduction of new and innovative products by key Molecular Diagnostics Companies, among others, is expected to drive the Molecular Diagnostics Market from 2025 to 2032.